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ABSTRACT OF THE DISSERTATION
Modulation of T Lymphocytes by Tumor-Released Survivin
by
Jessica M. S. Jutzy
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, December 2014
Dr. Nathan R. Wall, Chairperson

The tumor microenvironment is an area of intense interaction between normal and
malignant cells. Factors and cell types within this environment can play a crucial role in
the progression or regression of the tumor. Of primary interest are tumor-infiltrating T
lymphocytes, which have been shown to have a key role in modifying the dynamics of
the tumor microenvironment to promote or prevent tumor growth. While there is much
in vitro and in vivo evidence for a modification of the tumor infiltrating T cell population
toward a pro-tumor environment, what induces these changes within the tumor
microenvironment has remained elusive. Our lab previously identified a role for the
Inhibitor of Apoptosis protein Survivin as a secreted protein in the extracellular milieu,
where it is capable of entering malignant cells and inducing a more aggressive phenotype.
We hypothesized that tumor-secreted Survivin could be responsible for modulation of T
lymphocytes in the tumor microenvironment. We first isolated tumor released Survivin
and confirmed it’s ability to be taken up by T cells as it is by malignant cells by confocal
microscopy, flow cytometry and Western blotting. Subsequently, we evaluated
Survivin’s affect on T cell proliferation and found that tumor-released Survivin impairs T
cell expansion, but does not alter its activation after exposure to appropriate stimuli.
Assessment of phenotypic changes within the cytotoxic and helper T lymphocyte

xiii

populations showed an increase in anti-inflammatory type 2 T cells and a reduction in
type 1 T cells, which correlates to what has been observed in cancer patients. Although
often modified in the tumor microenvironment in patients, we did not observe and
changes in regulatory T cells or Th17 cells in the presence of Survivin. The results of
this study provide evidence of Survivin’s role as an extracellular mediator of the tumor
microenvironment, specifically its role in inducing a pro-tumor type 2 T cell population.
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CHAPTER ONE
INTRODUCTION
Cancer
Characteristics of Cancer Cells
Cancer is a complex disease involving the accelerated and uncontrolled
proliferation of abnormal cells that invade normal tissues. While each type of cancer has
different morphology, treatment and prognosis, several key features remain common
throughout. Six hallmarks were originally described by Hanahan and Weinberg in 2000,
most of them involving molecular changes within cancer cells themselves (Figure 1.1).
The definition of these features and their consolidation into one picture of cancer
provided a model through which cancer progresses, eventually gaining these functions to
reach the malignant state (Hanahan D and Weinberg RA 2000).
The first of these hallmarks is the ability of cancer cells to replicate without limit,
providing them with a never-ending proliferative capacity (Hanahan D and Weinberg RA
2000). While normal human cells have a replicative capacity of approximately 60-70
divisions, malignant cells frequently exceed this limit, providing enough cells to form a
tumor despite death of many of the pre-malignant cells along the way (Wyllie AH et al.
1980; Bergers G et al. 1998). This function of cancer cells to continue to divide past the
typical threshold of normal cells was found to be aided by induction of telomerelengthening functions within these cells. In a normal cell, the chromosome ends, or
telomeres, shorten every time the DNA is replicated, until eventually the ends are
degraded to the point of inducing apoptosis of the cell (Counter CM et al. 1992). By
upregulating factors that preserve telomere length (telomerase, ALT) the normal
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proliferative capacity can be greatly exceeded by the malignant cell, resulting in tumor
formation (Hanahan D and Weinberg RA 2000).
The next two hallmarks go hand-in-hand to push the unrestrained proliferation
allowed by the telomere lengthening mentioned previously: 1. Self-sufficiency in growth
signals and 2. Insensitivity to anti-growth signals. In the normal cell, growth is only
induced when a need of the body requires it. Some cell populations, like hematopoietic
cells and gastric epithelial cells, replicate frequently due to wear and tear, while others
replicate in the context of a specific need or after injury. The promotion of this renewal
is mediated by growth factors and mitotic signals transmitted through surface and
intracellular receptors (Fedi P et al. 1997). On the opposing side, anti-growth signals in
the extracellular matrix and milieu prevent the proliferation of cells when not needed as
well as excessive growth of cells after the necessary divisions have occurred by inhibiting
the cell cycle. Malignant cells alter both sides of this control mechanism to allow their
unrestrained growth. By inducing their own mitotic signals by either production of
growth factors (PDGF, TGF-α) or altering the receptor-signaling cascade (Her2/neu, BcrAbl) they can continue to proliferate even when exogenous growth factors have been
withdrawn. Additionally, by disrupting normal pathways that block the cell cycle, such
as the retinoblastoma (pRB) and p15INK4B pathways, their endogenous growth factors
push forward unchecked (Fynan TM and Reiss M 1993; Zuo L et al. 1996; Datto MB et
al. 1997). Throughout the process of DNA replication and cellular proliferation, errors
frequently occur that must be detected by the cell to maintain cellular integrity (Hanahan
D and Weinberg RA 2000). Upon detection, cells are given the chance to repair the
mistakes and continue their division or are forced to die if the errors cannot be corrected.
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Figure 1.1. The hallmarks of cancer. From Hanahan and Weinberg 2000 and 2011, a
schematic of the original (top) and emerging (bottom) characteristics of cancer.
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The rapid and uncontrolled proliferation provided by the hallmarks we have
discussed thus far provide many opportunities for error that would likely lead to
apoptosis in the normal cell. To prevent the likely death that would occur from
replication infidelity in the malignant cell mechanisms to inhibit apoptosis are necessary.
It has been stated that evasion of apoptosis is the largest barrier a cancer cell must
overcome, as studies have shown that induction of the previously mentioned hallmarks
alone result in the apoptosis of a large proportion of the cells (Kerr JF et al. 1972;
Bergers G et al. 1998). The evasion of apoptosis is mediated by multiple factors within
the cell including the Inhibitor of Apoptosis (IAP) protein and Bcl-2 family members
(Hanahan D and Weinberg RA 2000). By interfering with the caspase machinery and
mitochondrial-mediated death anti-apoptotic molecules can prevent death of malignant
cells in response to replicative errors and cellular stressors.
The final two hallmarks are vital to the advancement of malignancy past the point
of a small focal lesion. To continue its growth the tumor must have access to nutrients
and the ability to move past tissue barriers. The angiogenic potential allows for the tumor
to maintain access to a nutrient blood supply by extending vessels and inducing new
vessel growth into the tumor mass (Bergers G et al. 1998; Hanahan D and Weinberg RA
2000). This is primarily mediated by increased cancer cell production of pro-angiogenic
vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGF1/2) and
reduced production of anti-angiogenic factors thrombospondin-1 and β-interferon
(Bergers G et al. 1998). With a nutrient supply available, the only remaining barrier to
tumor growth is the boundaries of the tissue compartment it is contained within. Through
production of matrix metalloproteinases (MMPs) and decreasing cell-cell adhesion
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molecules like E-cadherin, cancer cells can move away from the tumor and past the
basement membrane barrier to invade nearby tissues as well as metastasize to distant
locations (Coussens LM and Werb Z 1996; Bergers G and Coussens LM 2000). This
metastatic function is part of what makes treatment of cancer incredibly difficult, as
simple surgical techniques cannot be used systemically to eradicate the malignancy.
As research in the field of cancer progressed, an updated version to this seminal
review of cancer was released (Hanahan D and Weinberg RA 2011). In 2011, Hanahan
and Weinberg released “Hallmarks of Cancer: The Next Generation,” bringing several
new players to the forefront of the cancer research world (Figure 1.1). Several of these
characteristics revolve around the interaction of the tumor and normal cells within the
tumor microenvironment.

The Tumor Microenvironment
The Role of Fibroblasts
Within the body of the tumor there are a variety of cell types, both malignant and
normal and as with normal tissue biology it is critical to understand the interactions
between the variety of cellular players to understand how it functions. The presence of
fibroblasts, endothelial cells and vessels are utilized by the tumor for protection, structure
and nutrient support (Hanahan D and Weinberg RA 2011). Fibroblasts play a vital role in
normal tissues by production of the extracellular matrix and its ground substance and
through the production of cytokines (Whiteside TL 2008). They are also crucial to
proper wound healing, with fibroblasts and myofibroblasts initiating wound contracture
and closure. In malignancy, fibroblasts help form the structural foundation for the tumor.
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Additionally, myofibroblasts, which normally make up only a small portion of normal
tissue structure, are increased in tumors. Since myofibroblasts are also increased in
chronic inflammation-induced fibrosis, it is thought that inflammation in the tumor
microenvironment increases the proportion of myofibroblasts (Liao Y et al. 2007;
Whiteside TL 2008). The importance of this increase in myofibroblasts has been
demonstrated in their ability to enhance tumor metastatic and angiogenic potential (De
Wever O et al. 2004; Karnoub AE et al. 2007).

Immune Cells
The tumor microenvironment is also home to a large number of immune cells, the
role of which has been intently investigated. The role of immune cells in the progression
or prevention of cancer and within the tumor microenvironment has been intently
debated. Both anti-tumor and pro-tumor effects have been characterized and it now
appears it is the balance of these factors and the tumor’s ability to modulate this balance
that determines what part the immune system will play in the development in cancer.

Macrophages
Macrophages are myeloid-derived immune cells that function to phagocytose and
kill pathogens and present their antigens to the adaptive immune system. Within the
tumor microenvironment macrophages are reprogrammed so that instead of activating the
adaptive immune response, they quench it (Liao Y et al. 2007). This can be explained by
the dual nature of macrophages. As is seen in many immune cell populations,
macrophages exist as either M1 or M2 cells. The type 1 or M1 phenotype is primarily
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pro-inflammatory and has an excellent capacity for killing cancer cells, presenting their
antigens and activating an adaptive immune inflammatory response against the tumor
(Liao Y et al. 2007). These functions are mediated by production of tumor necrosis
factor alpha (TNF-α) and nitric oxide (NO). However, because these functions require
the presence of oxygen, within the hypoxic tumor microenvironment, they are readily
diminished. The type 2 or M2 phenotype of macrophages plays a more permissive role in
the tumor microenvironment. Their production of growth factors such as VEGF promote
tumor angiogenesis and sustenance (DeNardo DG et al. 2009). Release of IL-10 and
prostaglandins by M2 cells diminishes the immune response by Natural Killer (NK) cells
and inflammatory T lymphocytes, providing a safe environment for the tumor (Liao Y et
al. 2007; DeNardo DG et al. 2009).

Dendritic Cells
Dendritic cells (DCs) are an important driving force in the immune response as
they are the most potent antigen presenting cells. The induction of an immune response
or the production of anergy in adaptive immune cells is partly dependent on their
maturity, with immature cells producing anergy and mature cells potently activating the
adaptive immune response (Liao Y et al. 2007). Mature dendritic cells predominate in
most tissues in order to provide activation of the adaptive immune system upon detection
of a pathogen, however, within the tumor microenvironment there is a preponderance of
immature DCs, while mature DCs are a rarity. Increased amounts of VEGF can impair
DC maturation and it is suspected that other cytokines produced in the tumor
microenvironment play an additional role (Liao Y et al. 2007).
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B Lymphocytes
The role of B lymphocytes has been investigated in several different cancer types
including breast, colorectal, melanoma and ovarian cancers (Hansen MH et al. 2002;
Galon J et al. 2006; Milne K et al. 2009; Erdag G et al. 2012). It is currently unclear if
the predominant function of B cells in the tumor microenvironment is pro- or anti-tumor
(Linnebacher M and Maletzki C 2012). Studies in breast cancer has shown that greater
than 40% of patients have anti-tumor antibody production by B cells that correlate to a
more favorable outcome (Hansen MH et al. 2002; Kotlan B et al. 2005). Additionally, in
lung and breast carcinoma, antibodies produced by B cells in the tumor
microenvironment may aid in tumor elimination (Kotlan B et al. 2005). In contrast,
studies in mice have shown that B cells may interfere with T cell eradication of tumor
cells (Liao Y et al. 2007). Determining the precise role of B cells in other malignancies
is an area of intense research with many questions left to be answered, including if they
primarily promote or hinder cancer progression.

T Lymphocytes
The role of T lymphocytes in malignancy is complicated at best. Multiple T cell
phenotypes have been shown to play a role in the progression or elimination of cancer,
depending on the cancer type (Nakayama H et al. 2000; Chikamatsu K et al. 2007;
Schreck S et al. 2009). Four main players have emerged in the T cell reaction to
malignancy, and the balance of them can alter tumor progression (Figure 1.2). They
include Type 1 and Type 2 T lymphocytes, regulatory T lymphocytes (Tregs) and IL-17
secreting T lymphocytes (Th17) (Zhu J and Paul WE 2008; Kryczek I et al. 2009).
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Type 1 and Type 2 T Lymphocytes. Type 1 T cells are comprised of both CD4+
helper and CD8+ cytotoxic populations, Th1 and Tc1, respectively. The defining
characteristic of these cells is their cytokine profile, which consists of tumor necrosis
factor alpha (TNF-α), gamma interferon (IFN-γ), and interleukin 2 (IL-2) (Woodland DL
and Dutton RW 2003). The type 1 T cell cytokine IFN-γ is vital to the anti-tumor
response as it recruits and activates macrophages, as well as increasing the cytotoxic
response by CD8+ T cells. Mice deficient in IFN-γ have been shown to spontaneously
develop tumors and have poor tumor clearance, illustrating the importance of IFN-γ in
anti-tumor immunity (Riemensberger J et al. 2002). Production of IL-2 by type 1 cells
increases the proliferation of nearby T cells, aiding the immune response by inducing
clonal expansion of tumor-reactive cells.
The antagonists of type 1 cells are the type 2 Tc2 and Th2 cells, which release IL4, IL-5, IL-6, IL-10 and IL-13 (Zhu J and Paul WE 2008). Type 2 cytokines prevent the
differentiation of naïve T cells into type 1 cells and oppose the functions of type 1
cytokines. IL-10 decreases the cytotoxic response by decreasing antigen presentation by
macrophages to Th1 cells, while IL-4 leads to decreased type 1 cell differentiation and
IFN-γ production (Wurtz O et al. 2004). In cancer, IL-4 has been shown to prevent
apoptosis of malignant cells, as well as increase the metastatic potential of breast cancer
cells through polarization of infiltrating macrophages (DeNardo DG et al. 2009).
Peripheral blood and intratumoral T cells from cancer patients frequently have an
imbalance in type 1 and type 2 T cell populations (Filella X et al. 2000; Nakayama H et
al. 2000; Mainou-Fowler T et al. 2003; Murakami H et al. 2004; Sharma A et al. 2010).
Type 1 responses are typically decreased with a concomitant increase in type 2 cell
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numbers and cytokine levels. The potential for metastasis and angiogenesis is increased
by the presence of IL-4 and IL-6, respectively, both of which are produced by type 2 T
cells (Naldini A et al. 2003). This shift in the balance of type 1 and type 2 T cells has
been correlated to poor disease progression, as the anti-tumor response is inhibited and a
pro-tumor environment is created.
Regulatory T Cells. Characterized as CD4+CD25+CD127lowFoxp3+, regulatory
T cells (Tregs) are important in preventing immune responses to autoantigens and overactivation of the inflammatory response (Liu W et al. 2006). Treg cells have been
implicated in promoting tumor growth by suppressing activation of tumor-specific
cytotoxic T cells due to their expression of auto-antigens by production of Transforming
Growth Factor-β (TGF-β), cytolysis, and the induction of anergy (James E et al. 2010).
In addition to suppressing the immune response, Tregs are also able to promote cancer
stem cells. The regulation of cancer stem cells by Tregs is mediated by secretion of
TGF-β, which promotes microsphere formation (Penuelas S et al. 2009). As with type 2
T cells, increased numbers of Tregs within the tumor correlates with poor prognosis and
decreased responsiveness to immunotherapies (Chattopadhyay S et al. 2006; Clarke SL et
al. 2006; Chikamatsu K et al. 2007; James E et al. 2010; Sellitto A et al. 2011;
Yamagami W et al. 2011).
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Table 1
Cytokines released by type 1 and type 2 T cells and their functions in malignancy.
Cytokine

Interferon-γ
Type 1
Interleukin-2

Interleukin-4
Type 2
Interleukin-6
Interleukin-10

Function
Differentiation of naïve T cells into type 1 T
cells
Inhibition of the type 2 T cell response
Increased cytotoxic CD8+ T cell response
Activation of macrophages
Induction of T cell proliferation
Clonal expansion of anti-tumor T cells
Inhibition of the type 1 T cell response
Reduced interferon-γ production
Prevention of cancer cell apoptosis
Polarization of tumor-infiltrating macrophages
Increased metastatic potential
Increased angiogenic potential
Differentiation of naïve T cells into type 2 T
cells
Decreased cytotoxic CD8+ T cell response
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Figure 1.2. The divisions of T cell response. A naïve T cell can become a type 1
(orange), type 2 (blue), Treg (purple) or Th17 (green) cell based on the cytokines it is
exposed to when activated. Upon differentiation, each cell type secretes a characteristic
cytokine profile.
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Th17 Cells. Pro-inflammatory CD4+ Th17 cells produce IL-17 to recruit
neutrophils and induce the production of pro-inflammatory factors in immune cells
(Kryczek I et al. 2009; Maniati E et al. 2010; Reynolds JM et al. 2010). The role of
Th17 cells in cancer is still unclear. The inflammatory Th17 response correlates with
poor disease outcome in prostate, head and neck and colorectal cancer. This is
hypothesized to be due to production of the anti-inflammatory mediator prostaglandin-E2
(PGE2) and pro-angiogenic hypoxia-inducible factor 1-alpha (HIF1α) (Penuelas S et al.
2009). However, IL-17 knockout mice exhibited increased susceptibility to metastasis of
colon cancer MC38 cells, demonstrating a possible anti-tumor function of Th17 cells
(Maniati E et al. 2010). Th17 cells reduce Treg cell numbers by lowering TGF-β release
and increase cytotoxic T cell function by secretion of IL-21 (Penuelas S et al. 2009).
Although the precise mechanism of Th17 induction is still unclear, it appears that in
malignancies initiated by inflammation, high numbers of Th17 correlate with poor
prognosis due to their role in the induction of inflammation and angiogenesis (Yang ZZ
et al. 2009). In tumors that were not initiated by an inflammatory response, Th17 cells
may be beneficial in activating a cytotoxic immune response to eradicate the tumor
(Yang ZZ et al. 2009).
Although all of these changes that occur to the immune cells in the tumor
microenvironment have been documented in patient and animal models, the precise
mechanism that causes them is not well understood. While we have evidence for a role
for hypoxia in skewing the tumor-infiltrating macrophage population, the same cannot be
said for T cells. There are several hypotheses, one of which is the idea that one or more
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factors released by the tumor itself is likely a cause for this change in the T lymphocyte
population.

Survivin
Survivin as a Member of the Inhibitor of Apoptosis Family
Survivin is a 142 amino acid protein and member of the Inhibitor of Apoptosis
(IAP) protein family. As a member of this family it contains a baculoviral inhibitor of
apoptosis repeat (BIR) domain, so named because the original members of the IAP
family (Cp-IAP and Op-IAP) were found to use this domain to bind and inhibit caspases
in baculoviruses (Crook NE et al. 1993; Clem RJ and Miller LK 1994). In humans,
Survivin and its other IAP family members (XIAP, c-IAP1, c-IAP2, and NAIP) have
been shown to inhibit programmed cell death (Liston P et al. 1996; Ambrosini G et al.
1997). However, unlike its other family members, Survivin does not contain the typical
RING zinc finger or the caspase-recruitment domain (CARD) necessary for their antiapoptotic function. Despite lacking these domains, Survivin is capable of preventing
apoptosis signaled by TNF-α and Fas/FasL.

Anti-Apoptotic Function and Role in Cancer
Members of the IAP family typically prohibit programmed cell death through
direct interaction with caspases, particularly activated caspase-3 and -7 (Deveraux QL et
al. 1997; Roy N et al. 1997). With Survivin, the mechanism by which it inhibits
apoptosis is not as clear. Some research has suggested that Survivin inhibits caspases-3
and -7 directly (Tamm I et al. 1998; Shin S et al. 2001), while others have suggested that
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there is no interaction with caspase-3 (Banks DP et al. 2000). Still others have suggested
Survivin’s anti-apoptotic effect is through inhibition of caspase-9 due to its ability to bind
caspase-9 on the mitotic spindle and its ability to prevent staurosporine-induced death
(O'Connor DS et al. 2000; Chandele A et al. 2004). While the precise mechanism by
which Survivin prevents cell death is uncertain, it is known that Survivin can prevent
Bax- and Fas-induced apoptosis (Ambrosini G et al. 1997; Tamm I et al. 1998).
Survivin’s overexpression has been documented in most, if not all, types of
cancer, and high levels of it have been linked to poorer prognosis in small cell lung
cancer, non-small cell lung cancer, hepatocellular carcinoma, and colorectal carcinoma
(Kawasaki H et al. 1998; Monzo M et al. 1999; Ikeguch M et al. 2002; Ikehara M et al.
2002). Survivin expression is also detectable in normal fetal development. In situ
hybridization in chick embryos found that Survivin is expressed in the majority of fetal
tissues, including lung, kidney and dorsal root ganglion. In mouse embryos, Survivin
expression was ubiquitous throughout all tissues(Adida C et al. 1998). However, after
fetal development Survivin expression is dramatically reduced or absent in mature human
tissues. It is likely that through demethylation of the survivin gene promoter, malignant
and pre-malignant cells are able to overexpress Survivin and evade apoptosis to go on to
produce disease (Hattori M et al. 2001).

Survivin’s Function in Cell Cycle Regulation
Survivin expression can be detected both in the cytoplasm and nucleus throughout
the cell cycle, but its expression peaks during the G2/M phase of the cell cycle (Li F et al.
1998). This nuclear and cell-cycle regulated expression led to the idea that Survivin may
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play a role in cell proliferation. Indeed, upon further investigation it was found that
Survivin is a component of the chromosomal passenger complex (CPC) along with
Aurora-B and Borealin (Lens SM et al. 2006; Canovas PM and Guadagno TM 2007). Its
function in the cell cycle includes organization of the central spindle and correction of
spindle attachment errors to allow cell division. This function is seen not only in
malignant cells, but also in T lymphocytes. Upon T cell activation and clonal expansion,
Survivin is upregulated to aid in the rapid proliferation that occurs (Song J et al. 2005).

Survivin in Immune Cell Modulation
Survivin has a well-documented role in malignancy, but recent research shows it
has an additional function in inflammation and autoimmunity. The amount of Survivin in
the synovial fluid of rheumatoid arthritis patients has been correlated to a more severe
disease progression (Bokarewa M et al. 2005). It is thought that synoviocytes, which
resemble fibroblasts, may be the source of Survivin production in patients with
rheumatoid arthritis (Ahn JK et al. 2010). Additionally, when recombinant Survivin was
added to immune cell cultures, it was found to upregulate adhesion molecules CD11b and
CD11c on granulocytes and monocytes. Similar adhesion molecule profiles were
observed in rheumatoid arthritis patients with high levels of synovial fluid Survivin
(Mera S et al. 2008).

Survivin as an Exosomal Protein
In addition to its cytosolic (Fortugno P et al. 2002), nuclear (Fortugno P et al.
2002) and mitochondrial (Dohi T et al. 2004) localization, Survivin has also been found
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in the extracellular milieu and in exosomes secreted by cancer cells (Khan S et al. 2009;
Khan S et al. 2011). Survivin has been shown to colocalize with Hsp70 in exosomes
isolated from cancer cell-conditioned medium, demonstrating a novel pool of Survivin.
Extracellular and exosomal Survivin has been shown to be taken up by malignant cells,
resulting in altered function and increased aggressiveness (Khan S et al. 2009). Upon
uptake into cancer cell lines, extracellular Survivin is able to induce proliferation and
invasive potential as well as increase their resistance to UV radiation and chemotherapy.
The exact mechanism that allows localization of Survivin into the exosome and its
subsequent uptake into nearby malignant cells is not completely understood and is
currently under investigation. However, it has been shown that increased cellular stress
by sublethal doses of proton radiation enhances packaging of Survivin in exosomes,
resulting in increased release of Survivin into the tumor microenvironment (Khan S et al.
2011).
Purpose of Study
While the role of T cells in cancer and their phenotypic alteration has been
thoroughly assessed, the driving force behind this alteration is still not clear. Because of
Survivin’s extracellular release by exosomes and its ability to modulate leukocytes in
autoimmune disease, we propose that Survivin within the tumor microenvironment could
modify the T cell response to promote tumor growth. In order to evaluate this hypothesis
we first sought to confirm that Survivin could be taken up by T lymphocytes in a similar
manner as observed in malignant cells. Secondly we defined the effect of Survivin on
cytotoxic CD8+ T lymphocyte cytokine release and cytotoxic function. Lastly, we
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evaluated Survivin’s ability to skew normal T lymphocytes toward a type 2 phenotype,
which would aid cancer cells by decreasing anti-tumor inflammation.
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CHAPTER TWO
ISOLATION AND T CELL UPTAKE OF TUMOR-RELEASED
SURVIVIN
Introduction
Survivin is a member of the Inhibitor of Apoptosis (IAP) protein family that has
been shown to prevent cell death induced by the Fas/FasL, Bax and caspase
pathways(Ambrosini G et al. 1997; Tamm I et al. 1998). This multi-functional protein
also acts as a cell cycle regulator and is expressed in the G2/M phase to aid in
proliferation. The proliferative and anti-apoptotic bi-functionality of Survivin makes it
an essential component in the life of a cancer cell. Survivin has been found in the
cytosol, mitochondria and nucleus of the cell (Fortugno P et al. 2002; Dohi T et al. 2004),
as well as extracellularly in exosomes (Khan S et al. 2009; Khan S et al. 2011). The
packaging of Survivin into exosomes allows its release into the tumor microenvironment
where it is taken up by other cancer cells (Khan S et al. 2009; Khan S et al. 2011). This
uptake of Survivin by malignant cells results in increased proliferative and invasive
potential as well as resistance to chemotherapy (Khan S et al. 2009).
In addition to cancer cells, fibroblasts and immune cells populate the tumor
microenvironment. While cancer cells take up extracellular Survivin, normal fibroblasts
and epithelial cells, which normally do not express Survivin, show no uptake (Khan S et
al. 2009). Some normal cells, such as T lymphocytes, do express low levels of Survivin
causing us to question the ability of these normal cells to take up Survivin from the
extracellular space. T lymphocytes are found abundantly within the tumor
microenvironment, and frequently are modulated by the tumor to be less cytotoxic,

19

preventing tumor attack. If Survivin is taken up from the extracellular space by T
lymphocytes it could point towards a role for Survivin in T lymphocyte modulation in the
tumor microenvironment.
We isolated tumor-released Survivin from conditioned medium using the pOZNSurvivin-WT cell line, which secretes a FLAG-HA-tagged Survivin. Survivin was pulled
down using dual-affinity immunoprecipitation and quantified by Enzyme-Linked
Immunosorbant Assay (ELISA). Evaluation of uptake showed that both malignant cells
and T lymphocytes could indeed take up the purified Survivin. Additionally, because
excess Survivin was observed to be toxic to normal T lymphocytes in large amounts, we
determined the sublethal dose of our purified Survivin that could be used in our future
studies. The results in this chapter provided the preliminary results that lead us to our
findings in the subsequent chapters.

Results & Discussion
Uptake of Purified FLAG-HA-Survivin in T Lymphocytes
Isolation and Quantification of Survivin from Conditioned Medium
We isolated a FLAG-HA tagged Survivin from the conditioned medium of HeLaS cells. This was accomplished using the pOZN-Survivin-WT cell line; a cervical
carcinoma HeLa-S cell line engineered to overexpress a FLAG-HA-tagged wild-type
Survivin (Khan S et al. 2009). The pOZN-Survivin-WT cells were grown in a bioreactor
and the conditioned medium collected after 24 hours. After eliminating cellular debris by
serial centrifugation, Survivin was isolated from the conditioned medium by
immunoprecepitation (IP) using anti-FLAG and anti-HA antibodies. Quantification of
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the purified Survivin was done using a Survivin-specific ELISA and found to be 1.25
pg/μl.
While we had already shown that Survivin from conditioned medium could be
taken up by cancer cells (Khan S et al. 2009), we needed to evaluate their ability to take
up our purified Survivin. HeLa-S cells were cultured with various concentrations of
isolated FLAG-HA-Survivin or conditioned medium and Survivin uptake evaluated by
immunofluorescence microscopy. Figure 2.1 shows that at 0.625-12.5 pg/ml there is
visible uptake of FLAG-HA-Survivin by anti-HA staining, comparable to what was seen
in cells cultured with conditioned medium.

Isolation of T Lymphocytes and Determination of Sublethal Dose
Due to the fragile nature of primary T lymphocytes, we sought to determine what
dose of extracellular Survivin could be used without causing significant toxicity. CD3+ T
lymphocytes were isolated from the peripheral blood of normal volunteers by
centrifugation on Ficol-Hypaque solution, followed by magnetic separation. Peripheral
blood mononuclear cells (PBMCs) were isolated from the buffy layer and incubated with
biotinylated antibodies against CD3. Using streptavidin magnetic beads the T
lymphocytes were separated from other PBMCs on a magnetized column and then eluted.
These cells were then cultured with 0-10 pg/ml FLAG-HA-Survivin and viability
evaluated by 7-AAD staining and flow cytometry. The percentage of cell death increased
with increasing doses of Survivin as shown in Figure 2.2. Based on this data we chose to
use 1.25 pg/ml in our subsequent experiments.
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Figure 2.1. Uptake of purified FLAG-HA-Survivin by HeLa-S cells. FLAG-HASurvivin was isolated by immunoprecipitation from conditioned medium and added to
cultured HeLa-S cells for 24 hours. Uptake at various concentrations was evaluated
using immunofluorescene microscopy. Staining shows uptake at all concentrations
equivalent to the conditioned medium positive control (Blue = DAPI; Red = HA).
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Figure 2.2. Analysis of T lymphocyte death with increasing Survivin concentration.
Isolated T lymphocytes were incubated for 24 hours with FLAG-HA-Survivin at
various concentrations. Cells were analyzed for death by 7-AAD staining and flow
cytometry and showed an increase in cell death with increasing concentrations of
Survivin. Gating scheme and percent dead cells are shown (*p< 0.05, *** p<0.001).
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Evaluation of Survivin Uptake in T Lymphocytes
To determine if T lymphocytes can take up extracellular Survivin as cancer cells
do, our isolated CD3+ T lymphocytes were cultured with 1.25 pg/ml FLAG-HA-Survivin
and evaluated for Survivin uptake by confocal microscopy as shown in Figure 2.3. Due
to the narrow ring of cytoplasm surrounding each cell, it was difficult to determine the
location of Survivin by confocal microscopy alone. The pyknotic staining of Survivin
made it appear that it may be on the surface of the cell and not within the cytoplasm. To
further assess this, Survivin uptake was evaluated by immunofluorescence microscopy
with β-actin colocalization. As shown in Figure 2.4 there are areas of yellow staining
where both the β-actin (red) and FLAG-HA-Survivin (green) are colocalized, as well as
separate pyknotic green staining areas, showing that Survivin is both within the
cytoplasm, as well as on the cell surface.
Further characterization of this uptake was performed using flow cytometry by
both surface and intracellularly staining for Survivin and HA from 0-720 minutes after
the addition of extracellular Survivin (Figure 2.5A,B). Beginning at 5 minutes, there is a
similar amount of Survivin staining on the surface as well as intracellularly, followed by
increased intracellular Survivin staining over time. These results indicate an initial
surface binding of Survivin on T lymphocytes and a subsequent entry into the cytoplasm
of the cell. Additionally, Western blot analysis of FLAG-HA-Survivin uptake in T
lymphocytes showed that after entry into the cell, Survivin persists for at least 96 hours as
demonstrated in Figure 2.5C.
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Figure 2.3. Confocal microscopy of Survivin uptake
were incubated with FLAG-HA-Survivin for 24
antibodies for confocal microscopy. Images show
Pyknotic FLAG-HA-Survivin staining is seen on
Red=HA).
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by T lymphocytes. T lymphocytes
hours and stained with anti-HA
1 micron slices through the cells.
the T lymphocytes (Blue=DAPI,

Figure 2.4. Colocalization analysis of Survivin uptake in T lymphocytes. T lymphocytes
were cultured with FLAG-HA-Survivin and stained for both FLAG and β-actin. White
arrow shows yellow colocalization of β-actin and FLAG, demonstrating the Survivin is in
the cytoplasm as well as on the surface (Blue=DAPI, Red= β-actin, Green=FLAG).
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Figure 2.5. Flow cytometric and Western analysis of Survivin uptake in T lymphocytes.
A. T lymphocytes were cultured with FLAG-HA-Survivin over time and analyzed for
surface binding and intracellular uptake. Some surface binding was observed throughout,
while intracellular levels increased over time. B. Graphical representation of flow
cytometry data (Mean Intracellular Fluorescence = Total Fluorescence – Surface
Fluorescence). C. Western analysis of T lymphocytes shows that FLAG-HA-Survivin
persists in the cells even up to 96 hours after removal from culture.
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Conclusions
The results of these studies show that indeed our purified FLAG-HA-Survivin can
be taken up by malignant cells, just as is seen in conditioned medium. Additionally and
most importantly, FLAG-HA-Survivin is able to bind to the surface of T lymphocytes as
well as enter into the cells. This finding, along with the persistence of FLAG-HASurvivin within the lymphocytes for several days after incubation, points to a potential
role for Survivin in immune evasion within the tumor microenvironment.

Materials & Methods
Collection of Conditioned Medium from pOZN-Survivin-WT Cells
FLAG-HA-Survivin pOZN-Survivin-WT cells were grown in a 5L bioreactor at
37C in Joklik medium supplemented with 10% FCS, L-glutamine and
penicillin/streptomycin. After 1 week of growth the conditioned medium was collected
and centrifuged at 3,000 x g for 5 minutes at 4C to remove cells. The supernatant was
then centrifuged at 10,000 x g for 10 minutes at 4C to remove cellular debris.

Isolation of FLAG-HA-Survivin from Conditioned Medium
Anti-FLAG beads (20 l/ml) were added to the centrifuged conditioned medium
and rotated overnight at 4ºC. The beads were pelleted by centrifugation and Survivin
eluted from the beads using FLAG peptides. This process was repeated using anti-HA
beads (20 l/ml). Free FLAG and HA peptides were removed from the preparation by
dialysis against a 10 mM HEPES buffer (pH 7.5) overnight at 4ºC. The concentration of
Survivin was 1.2 ng/ml as determined by ELISA (R&D Systems). Synthesized FLAG
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and HA peptides were added to 10mM HEPES buffer at a concentration of 1.2 ng/ml for
use as a control.

Culture and Treatment of HeLa-S Cells
HeLa-S cells were cultured in flasks in a 5% CO2 incubator with DMEM medium
supplemented with 10% FCS, L-glutamine and penicillin/streptomycin. To evaluate for
purified Survivin uptake, cells were cultured with conditioned medium from pOZNSurvivin-WT cells or with 0.0-12.5 pg/ml FLAG-HA-Survivin for 24 hours.

Isolation of T Lymphocytes from Peripheral Blood
Peripheral blood from normal, healthy donors was collected into potassium
EDTA vacuettes as approved by the Institutional Review Board at Loma Linda
University. Peripheral blood mononuclear cells (PBMCs) were isolated from the buffy
layer following centrifugation on a Ficoll-Hypaque gradient (GE Healthcare). PBMCs
were washed with cold Streptavidin Labeling Buffer (PBS with 2mM EDTA pH7.2) and
stained with anti-human CD3 biotinylated antibodies (BioLegend) at 4°C. Cells were
again washed with cold Streptavidin Labeling Buffer and then incubated with
Streptavidin magnetic microbeads. (Miltenyi Biotec) After an additional wash the cells
were added to a magnetic column and eluted from the CD3- cells. The isolated CD3+
cells were cultured in R10 medium (RPMI supplemented with 10% FBS, L-glutamine,
penicillin/streptomycin, and 0.1% 2-mercaptoethanol).
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Immunofluorescence and Confocal Microscopy
T lymphocytes or HeLa-S cells were cultured in 12-well plates in R10 or FLAGHA-Survivin medium. Cells were harvested after 24 hours in culture, fixed with 3.7%
paraformaldehyde and permeabilized with 0.1% PBS-saponin. Cells were stained with
anti-FLAG, anti-HA or anti-Actin primary antibodies and goat anti-mouse Alexa Fluor
488 or goat anti-rabbit Alexa Fluor 555 secondary antibodies (Invitrogen). Slides were
imaged using the Olympus BX50 fluorescent microscope or Zeiss LSM 710 NLO laser
scanning confocal imaging system, equipped with an Axio Observer Z1 inverted
microscope.

Flow Cytometry
T lymphocytes were cultured in 96-well plates in R10 or FLAG-HA-Survivin
medium at a concentration of 1x106 cells/ml. Cells were harvested at 5, 15, 30, 60, 120,
240, 360 and 720 minutes and stained for surface-bound or intracellular Survivin using
rabbit anti-FLAG, goat anti-rabbit Alexa Fluor 488 secondary (Invitrogen, Carlsbad,
CA), and anti-Survivin Alexa Fluor 647 antibodies (Cell Signalling, Danvers, MA). For
intracellular staining, cells were fixed and permeabilized using the eBioscience
Fixation/Permeabilization Kit (San Diego, CA). Cells were stained for T lymphocyte
surface antigens with monoclonal antibodies against CD3, CD4, and CD8 (BioLegend,
San Diego, CA). Data was collected on the MACSQuant flow cytometer (Miltenyi
Biotec, Auburn, CA) and analyzed with FlowJo analysis software.
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Western Blotting
For Western blots of Survivin uptake, T lymphocytes were cultured with FLAGHA-Survivin, harvested at 24, 48, 72, and 96 hours, and washed with PBS. Whole cell
lysates were prepared and separated using 12% Bis-Tris polyacrylamide gels run at
60mA for 45 minutes. Proteins were transferred onto nitrocellulose membranes at
350mA for 75 minutes. After blocking with Odyssey Blocking Buffer, membranes were
probed using mouse monoclonal anti-FLAG (Invitrogen), rabbit polyclonal anti-Survivin
(Novus Biologicals), and rabbit polyclonal anti-Actin (Cell Signalling). Secondary IRDye conjugated goat anti-rabbit and goat anti-mouse antibodies (LICOR) were utilized
and bands detected using the Odyssey imaging system (LICOR).
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CHAPTER THREE
MODULATION OF T LYMPHOCYTE PROLIFERATION BY
SURVIVIN
Introduction
Humoral and adaptive immune functions are crucial in the prevention of many
cancers. Cytotoxic CD8+ T lymphocytes normally aid in the prevention of cancer by
destroying abnormal or transformed cells (Rosenberg SA et al. 1998). The failure of
these responses have been implicated in the development and progression of many
cancers, but is exemplified in cancers induced by viral infection such as Burkitt’s
Lymphoma and nasopharyngeal carcinoma (Li J et al. 2007) and increased frequency of
malignancy in immunocompromised individuals (Vajdic CM and van Leeuwen MT
2009). Progression of malignancy is in part dependent on the tumor’s ability to evade
immune detection and cytolytic destruction by T lymphocytes (Hanahan D and Weinberg
RA 2011). Indeed, patients with ovarian cancer have significantly improved prognosis
when the tumor microenvironment is well infiltrated with cytotoxic T lymphocytes and
natural killer cells (Zhang L et al. 2003; Sato E et al. 2005). However, induction of the T
lymphocyte response does not always prevent progression of cancer, even in
immunocompetent individuals. The mechanisms by which this occurs have been
investigated and linked to reduced induction of T lymphocytes in response to the tumor
as well as T regulatory cell inhibition of the T lymphocyte response (Woo EY et al.
2001).
Due to Survivin’s critical role in cell proliferation, both in malignant cells and T
lymphocytes (Altieri DC 2003; Song J et al. 2005), and our previous findings that tumor-
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released Survivin effects malignant cell proliferation, we sought to evaluate the effects of
tumor-released Survivin on T lymphocyte activation and clonal expansion. In order to
determine the role of Survivin in the tumor immune response, we utilized our isolated
and purified FLAG-HA-Survivin to evaluate T lymphocyte proliferation, activation and
cytotoxic function. We noted a reduction in T lymphocyte proliferation in the presence
of tumor-released Survivin, while activation was not effected. Together this data
demonstrates a role for tumor-released Survivin in the impairment of the anti-tumor
response.

Results & discussion
Reduced Proliferation in Survivin-Exposed T Lymphocytes
To determine if Survivin uptake in T lymphocytes affects their ability to respond
to activating stimuli, we analyzed their proliferation using the cell-cycle-associated
nuclear antigen Ki-67 (Scholzen T and Gerdes J 2000), carboxyfluorescien succinymidyl
ester (CFSE) reduction and BrdU incorporation assays. T lymphocytes were isolated
from healthy, cancer-free donors, stimulated with anti-CD3/CD28 T cell expansion beads
and cultured in control medium, medium containing isolated FLAG and HA peptides, or
medium containing tumor-released FLAG-HA-Survivin. Expression of intracellular Ki67 was analyzed at 24, 48, 72 and 96 hours by flow cytometry. Figure 3.1 shows a
representative gating scheme for our flow cytometry data. T cells were selected by
positive CD3 staining and Figure 3.2A shows representative staining of Ki-67 at 72 hours
post-stimulation. At 72 and 96 h, Ki-67 expression was significantly decreased in both
CD8+ and CD4+ T lymphocytes when cultured with FLAG-HA-Survivin compared to

33

Control and FLAG-HA only medium (Figure 3.2B). This demonstrates decreased T cell
proliferation in the presence of Survivin.

34

Figure 3.1. Gating scheme for Ki-67 analysis. A. Lymphocytes were selected by their
Forward and Side Scatter profiles. B. T lymphocytes were selected by positive
staining for CD3. Ki-67 expression was analyzed on both C. CD4 and D. CD8 stained
populations.
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Figure 3.2. Ki-67 expression in T lymphocytes A. Representative gating
scheme of T lymphocyte Ki-67 expression. B. Normal T lymphocytes have
significantly decreased Ki-67 expression at 72 and 96 hours following
incubation with cancer cell-released FLAG-HA-Survivin compared to control
and FLAG-HA only medium. *p<0.05, ***p<0.001.
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To confirm these results we evaluated CFSE dilution in T lymphocytes. CFSE is
a cytosolic fluorescent dye used to detect proliferation, with a dilution of the dye
observed with each cell division (Lyons and Parish, 1994). If indeed Survivin is reducing
proliferation in these cells, the CFSE fluorescence of cells stimulated in the presence of
Survivin should be higher due to reduced dilution through proliferation compared to
controls. Helper and cytotoxic T lymphocytes were selected by CD4 and CD8 expression
respectively and analyzed for CFSE fluorescence intensity (Figure 3.3). CFSE staining
showed dilution in response to stimulation in Control and FLAG-HA only cells, which
was prevented by the addition of FLAG-HA-Survivin (Figure 3.4). This confirms are
intital Ki-67 data, showing that indeed the presence of tumor-released Survivin prohibits
T lymphocyte proliferation in the presence of activating stimuli.
Tertiary confirmation was done by a bromodeoxyuridine (BrdU) incorporation
assay. As cells replicate their DNA to prepare for division they incorporate the BrdU,
which can be detected by flow cytometry. We expected that in the presence of Survivin,
the number of cells that have replicated their DNA for division and have become BrdUpositive would be reduced if Survivin were indeed decreasing proliferation. T
lymphocytes were cultured with control medium or that containing FLAG and HA
peptides or FLAG-HA-Survivin and BrdU added after 72 hours in culture. Cells were
harvested 24 hours later and analyzed for nuclear BrdU by flow cytometry. T
lymphocytes cultured with FLAG-HA-Survivin showed significantly reduced percentage
of cells with BrdU incorporation (Figure 3.5).
Final confirmation was done by cell counting by flow cytometry to determine if
indeed a reduced number of cells was present due to this reduce proliferation observed by

37

our previous assays. After culture and stimulation total T lymphocyte numbers were
significantly decreased in FLAG-HA-Survivin cultures compared to controls (Figure
3.6A). Due to the fact that primary cells are far less resilient to the addition of exogenous
materials than malignant cell lines, it was necessary to rule out cell death as a reason for
this decreased proliferation and lower cell numbers. To quantify cell death in our
populations, we analyzed viability using 7-AAD staining and no significant difference in
viability was seen in FLAG-HA-Survivin compared to controls (Figure 3.6B). This data
shows that Survivin has an anti-proliferative affect in T lymphocytes.
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Figure 3.3. Representative gating scheme for CFSE analysis. T lymphocytes were
selected by their Forward and Side Scatter profiles and positive staining for CD3. Helper
and cytotoxic T lymphocyte populations were selected by CD4 and CD8 staining,
respectively.
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Figure 3.4. CFSE dilution in T lymphocytes. A. Plot of CFSE mean
fluorescence intensity. B. T lymphocytes have significantly decreased
CFSE expression at 72 and 96 hours after activation in control conditions.
CFSE dilution is reduced in cultures containing FLAG-HA-Survivin.
**p<0.01, ***p<0.001.
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Figure 3.5. BrdU incorporation in T lymphocytes. A. BrdU staining in CD4 and CD8
T lymphocytes. B. T lymphocytes show decreased BrdU incorporation in the
presence of Survivin compared to controls. **p<0.01, ***p<0.001.
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Figure 3.6. Cell number and viability analysis. A. Culture with Survivin results in
decreased numbers of both CD4+ and CD8+ T lymphocytes upon stimulation with antiCD3/anti-CD28. B. Viability analysis by 7-AAD shows no increased cell death in T
lymphocytes that are cultured with Survivin.
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Survivin’s ability to prohibit proliferation in T lymphocytes is in stark contrast to
the increased proliferative rate seen in malignant cells after Survivin uptake (Khan S et
al. 2009). One key difference between T lymphocytes and tumor cell proliferation is the
requirement of activation signalling for T lymphocyte clonal expansion (Morris J and
Waldmann T 2000; Song J et al. 2005). Survivin’s anti-proliferative effect on T
lymphocytes could be due to an interference with T cell activation.
To examine this possibility, T lymphocytes were stimulated in the presence or
absence of extracellular FLAG-HA-Survivin and analyzed for the expression of
activation markers CD25 and CD69. CD25, part of the high-affinity interleukin-2 (IL-2)
receptor, is expressed on T lymphocytes after activation to aid in the response to the proproliferative cytokine IL-2. CD69 is an activation marker that is upregulated on the
surface of T lymphocytes 2-4 hours after stimulation through CD3 signaling (Hamann J
et al. 1993). If Survivin is indeed interfering with the activation process, the expression
of these two molecules that require stimulation for expression would be significantly
reduced. We found that the addition of FLAG-HA-Survivin during stimulation had no
effect on the expression of activation antigens on T lymphocyte cultures (Figure 3.7).
This data shows that Survivin’s anti-proliferative effects are not mediated by interfering
with T cell activation through the T cell receptor-CD3 complex.
T lymphocytes are one of the few adult tissues that normally express Survivin.
Indeed, endogenous expression of Survivin is required for proper T cell activation and
proliferation (Song J et al. 2005). To determine if our exogenous FLAG-HA-Survivin
was altering endogenous Survivin levels we measured Survivin expression in stimulated
T lymphocytes in the presence of FLAG and HA peptides or FLAG-HA-Survivin by
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Western blot. The presence of exogenous FLAG-HA-Survivin does not significantly
alter Survivin protein expression levels after activation (Figure 3.8). From these results
we conclude the inhibition of proliferation by Survivin likely occurs after cells have been
activated and is not due to a reduction in activation-induced Survivin expression.
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Figure 3.7. Analysis of T lymphocyte activation. A. Flow cytometric
analysis of CD25 and CD69 activation markers after stimulation with
anti-CD3/anti-CD28. B. No significant difference in CD25 or CD69
expression was seen in T lymphocytes after culture with Survivin.
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Figure 3.8. Western blot of Survivin expression in activated T lymphocytes. The
addition of FLAG-HA-Survivin to T lymphocyte cultures does not significantly affect
the expression of endogenous Survivin after activation.
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Conclusion
Based on our data, we suggest that Survivin allows malignant cells to evade
immune detection be decreasing the ability of T lymphocytes to proliferate in response to
activating stimuli. From the evaluation of activation markers CD25 and CD69, Survivin
is not inhibiting T lymphocyte stimulation, but is possibly acting downstream of
activation signaling. Additionally, no changes in activation-induced endogenous
Survivin in the presence of FLAG-HA-Survivin were observed. Due to the significantly
diminished proliferation observed in both CD4+ and CD8+ populations from cancer-free
donors, we believe a similar effect would be seen in tumor-specific T lymphocyte and
overall T lymphocyte populations from cancer patients, though these studies have yet to
be accomplished.

Materials & Methods
Isolation of T Lymphocytes from Peripheral Blood
Peripheral blood from normal, healthy donors was collected into potassium
EDTA vacuettes as approved by the Institutional Review Board at Loma Linda
University. Peripheral blood mononuclear cells (PBMCs) were isolated from the buffy
layer following centrifugation on a Ficoll-Hypaque gradient (GE Healthcare). PBMCs
were washed with cold Streptavidin Labeling Buffer (PBS with 2mM EDTA pH7.2) and
stained with anti-human CD3 biotinylated antibodies (BioLegend) at 4°C. Cells were
again washed with cold Streptavidin Labeling Buffer and then incubated with
Streptavidin magnetic microbeads. (Miltenyi Biotec) After an additional wash the cells
were added to a magnetic column and eluted from the CD3- cells. The isolated CD3+
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cells were cultured in R10 medium (RPMI supplemented with 10% FBS, L-glutamine,
penicillin/streptomycin, and 0.1% 2-mercaptoethanol).

T Lymphocyte Proliferation Analysis by CFSE and Ki-67
T lymphocytes were stained with 0.5 M CellTrace carboxyfluorescein
succinimidyl ester (CFSE; Molecular Probes, Carlsbad, CA) for 15 min at 37C and the
reaction quenched with 5 volumes of cold R10 medium (RPMI supplemented with 10%
FBS, L-glutamine, penicillin/streptomycin, and 0.1% 2-mercaptoethanol). Cells were
plated in a 96-well plate at 2.5x105 cells/well in R10, FLAG-HA, or FLAG-HA-Survivin
medium, stimulated with anti-CD3/anti-CD28 T cell expansion beads (6.25 μl/well;
Invitrogen, Carlsbad, CA) and harvested at 0, 24, 48, 72, 96 and 120 hours. Cells were
stained for surface antigens CD3, CD4, CD8 and for viability using 7-AAD (BioLegend,
San Diego, CA). For Ki-67 analysis cells were cultured as above and harvested at 24, 48,
72, and 96 hours. Cells were stained for surface markers, fixed and permeabilized using
a Fixation/Permeabilization Kit (eBioscience, San Diego, CA) and stained for
intracellular Ki-67.

Analysis of T Lymphocyte Proliferation by BrdU Incorporation
T cells were plated in a 96-well plate at 2.5x105 cells/well in R10, FLAG-HA, or
FLAG-HA-Survivin medium and stimulated with anti-CD3/anti-CD28 T cell expansion
beads (6.25 μl/well; Invitrogen, Carlsbad, CA). At 72 hours in culture, 10 M BrdU was
added to each well and the cells harvested 24 hours after BrdU addition. Cells were
stained for surface CD3, CD4 and CD8, fixed and permeabilized using BD

48

Cytofix/Cytoperm Buffer (BD Biosciences, San Jose, CA), and frozen at -80C overnight
in freezing medium (10% DMSO, 90% heat-inactivated FBS). Cells were thawed,
washed using BD Cytofix/Cytoperm and then washed again with BD Perm/Wash Buffer,
after which they were re-fixed as before. Cells were treated with DNase (300g/ml) and
stained with anti-BrdU FITC (BD Biosciences, San Jose, CA) before analysis on the
MACSQuant flow cytometer.

Analysis of T Lymphocyte Activation
Isolated T lymphocytes were cultured and stimulated as described above. After
24 hours, cells were harvested and stained with monoclonal antibodies against CD3,
CD4, CD8 (BioLegend, San Diego, CA), CD25 and CD69 (BD Biosciences, San Jose,
CA) and analyzed by flow cytometry.

Western Blotting
To analyze Survivin expression after activation, T lymphocytes were cultured
with control, FLAG-HA or FLAG-HA-Survivin medium and activated using antiCD3/anti-CD28 T cell expansion beads (25 μl/ml; Invitrogen, Carlsbad, CA). Cells were
harvested at 0, 24, 48, 72, and 96 hours. Whole cell lysates were prepared and separated
using 12% Bis-Tris polyacrylamide gels. Proteins were transferred onto nitrocellulose
membranes and probed using rabbit polyclonal anti-Survivin (Novus Biologicals,
Littleton, CO) and rabbit polyclonal anti-Actin (Cell Signalling, Danvers, MA).
Secondary IR-Dye conjugated goat anti-rabbit antibodies (LICOR, Lincoln, NE) were
utilized and bands detected using the Odyssey imaging system (LICOR, Lincoln, NE).
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CHAPTER FOUR
ALTERATION OF CYTOTOXIC T LYMPHOCYTES BY
SURVIVIN
Introduction
Peripheral blood and intratumoral T cells from cancer patients frequently exhibit
altered T cell populations. Cytotoxic T lymphocyte (CTL) function is frequently
diminished as regulatory T cells (Tregs) increase and cytokine profiles are altered. Tregs
are a subset of the helper T lymphocyte population and are characterized by their
expression of the transcription factor Foxp3 (Chen W et al. 2003). Their primary
function is to prevent autoimmunity by inducing apoptosis or anergy in lymphocytes that
recognized self-antigens. Regulatory T cells have been implicated in promoting tumor
growth by suppressing activation of tumor-specific cytotoxic T cells due to their
expression of auto-antigens (Clarke SL et al. 2006; Sellitto A et al. 2011; Wang Z et al.
2011; Yamagami W et al. 2011). The balance of CTLs and Tregs in the tumor
microenvironment is dependent partly on the cytokine environment, as increased levels of
Transforming Growth Factor-β (TGF-β) induce naïve helper T cell differentiation into
Tregs, which go on to reduce CTL cytotoxic numbers and functions (Chen W et al.
2003). Increased numbers of Tregs and decreased numbers of CTLs within the tumor
correlates with poor prognosis and decreased responsiveness to immunotherapies (Ke X
et al. 2008). We hypothesize that Survivin can diminish cytotoxic T cell activity and
numbers through modulation of the cytokine environment and the induction of regulatory
T cells.
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Results & discussion
Cytotoxic Function in CD8+ T Lymphocytes
Tumor-specific cytotoxic T lymphocytes (CTLs) are important in the destruction
of cancer cells. As described in chapter three, we have observed decreased proliferation
of CTLs when stimulated in the presence of Survivin, which would likely diminish the
effectiveness of an anti-cancer T lymphocyte response. It is not known if Survivin also
alters the cytotoxic function of CTLs, so we evaluated this using a cytotoxicity assay.
CTLs were isolated from a single donor and cultured with Control, FLAG-HA or FLAGHA-Survivin medium and stimulated with PMA and ionomycin for 24 hours. The cells
were then added in culture with pooled peripheral blood mononuclear cells (PBMCs)
from other healthy donors at 5:1, 2.5:1 and 1.25:1 CTL:PBMC ratios. The ability of the
CTLs to kill foreign PBMCs was then evaluated using by lactate dehydrogenase release.
The cytotoxic function of CTLs was diminished at all CTL:PBMC ratios after culture
with FLAG-HA-Survivin compared to control conditions (Figure 4.1). This demonstrates
a possible immune evasion function for tumor-released Survivin by preventing CTLmediated killing.
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Figure 4.1. Cytotoxicity of CD8+ T lymphocytes. Cytotoxic T lymphocyte cytolytic
capabilities are reduced by pre-treatment with tumor-released Survivin. CD8+ cells
from a single donor were cultured with Survivin for 24 h and their cytotoxic function
assessed by the CytoTox 96 Non-Radioactive Cytotoxicity Assay. *p<0.05
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Regulatory T Lymphocyte Analysis
Evaluation of Regulatory T Lymphocyte Induction
The reduction of cytotoxic function in CD8+ T lymphocytes in the presence of
malignancy has been shown to be related to increased regulatory T lymphocytes (Treg) in
the tumor microenvironment (Chikamatsu K et al. 2007; Ke X et al. 2008). To determine
if the decreased CTL function observed in the presence of Survivin could be due in part
to Tregs, we evaluated the induction of Tregs after culture with Survivin. CD3+ cells
were cultured in control or Survivin containing medium with stimulation for 48 hours and
analyzed for the number of CD4+CD25+CD127low Treg cells by flow cytometry. No
differences were seen in the number of Tregs in the presence of Survivin compared to
controls (Figure 4.2).

Regulatory T Lymphocyte Function
To analyze the function of Tregs after culture with Survivin, CD4+CD127low
Tregs were isolated by magnetic separation. After 24 hours in culture with control,
FLAG-HA, or FLAG-HA-Survivin medium, the cells were washed and plated with
PBMCs and anti-CD3/anti-CD28 microbeads for 4 hours. Analysis of CD154 and CD69
levels on non-Treg cells was used to determine the ability of Tregs to suppress activation.
We observed that Treg function was not altered by culture with tumor-released Survivin
(Figure 4.3). Due to these results, the decreased cytotoxic function of CD8+ cells is likely
a direct effect of Survivin, and not through increased Treg numbers or function.
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Figure 4.2. Analysis of Regulatory T Lymphocytes A. Gating
scheme for regulatory T cells. B. No significance difference in the
amount of regulatory T cells was observed in the presence of
Survivin.
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Figure 4.3. Regulatory T Lymphocyte Function Assay.
CD3+CD4+CD127low Treg suppression capability was evaluated by
flow cytometry. No significant difference in Treg function was seen
between control and Survivin-treated cells.
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Cytotoxic T Lymphocyte Subset Analysis
Intracellular Cytokine Analysis
Although Survivin did not affect Treg function and numbers, CTL function was
significantly altered. The proportions of the subsets of cytotoxic T lymphocytes can have
a dramatic affect on the inflammatory response to malignant cells. Production of proinflammatory cytokines like IFN- can enhance CTL function, while anti-inflammatory
cytokines can suppress it. The proportion of these cytokines is controlled in part by the
proportion of type 1 and type 2 cytotoxic T lymphocytes. Type 1 CTLs (Tc1) are
characterized by their expression of IFN- and promote the overall cytotoxic functions of
surrounding CTLs, while type 2 CTLs (Tc2) release cytokines that blunt CTL function.
To evaluate the relative proportions of Tc1 and Tc2 cells we analyzed
intracellular cytokine expression by flow cytometry. Isolated T lymphocytes were
cultured in control, FLAG-HA only or FLAG-HA-Survivin medium for 48 hours and
then stimulated in the presence of cytokine release inhibitors. After 6 hours of
stimulation the cells were stained and evaluated for IFN-, IL-4, IL-5, and IL-13
expression. A significant reduction in CD8+IFN-+ Tc1 cells was seen after culture with
Survivin, demonstrating a reduction in pro-inflammatory cells (Figure 4.4A,B).
Additionally, CD8+ cells expressing the type 2 cytokines IL-5 and IL-13 increased
substantially in FLAG-HA-Survivin cultures though the change in IL-4 expressing CD8+
cells was not significant (Figure 4.4B).

Cytokine ELISA
To determine if the effects of Survivin on Tc1 and Tc2 numbers translates to
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changes in overall cytokine release by cytotoxic T lymphocytes, we evaluated CTL
cytokine release by ELISA. Isolated CD8+ cells were stimulated with anti-CD3/antiCD28 microbeads for 48 hours and PMA and ionomycin added for the final 6 hours. Cell
supernatants were isolated and analyzed for IFN-, IL-2, IL-4, IL-5, IL-10 and IL-13
release. Analysis of the cytokine profile showed that pro-inflammatory Tc1 cytokines
IFN- and IL-2 were dramatically reduced in Survivin treated cells (Figure 4.5), while
Tc2 cytokines remained unchanged. These changes in inflammatory cytokines may
contribute to the decreased cytotoxic activity observed in the presence of Survivin.
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Figure 4.4. Flow Cytometric Analysis of Cytotoxic T Lymphocyte Subsets. A.
Gating scheme for CD8+ T cell subsets. B. Survivin significantly decreases
CD8+IFN-γ+ cell numbers and increases CD8+Il-5+ and CD8+IL-13+ cell numbers.
***p<0.001.
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Figure 4.5. ELISA Analysis of Cytotoxic T Cell Cytokines. Type 1 cytokines are
decreased and Type 2 cytokines increased by Survivin. Cytokine ELISA shows
decreased production of inflammatory cytokines IFN-γ and IL-2 by CD8+ T cells. No
change was observed in anti-inflammatory IL-4, IL-5, IL-10 or IL-13 release.
***p<0.001.
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Conclusion
The results of our data show a decrease in cytotoxic activity in CTLs in the
presence of isolated tumor-released Survivin. While it was hypothesized that this was
due to modulation of the regulatory T cell population, we found that Survivin had no
significant effect on the numbers of Tregs, nor their ability to suppress activation in
response to stimuli. In contrast, it appears the effects on CTL cytotoxic function is more
likely to be caused by a shifting of the cytotoxic T lymphocyte population in the presence
of Survivin. IFN-γ has been shown to enhance cytotoxic killing functions of CTLs in
vitro and it is likely that the tremendous reduction in IFN-γ-producing cells and IFN-γ
release induced by Survivin is responsible for the decrease in cytotoxic function we
observed. Additionally, a similar shift in Tc1 and Tc2 populations and cytokine release
has been observed in cancer patients (Filella X et al. 2000; Ehi K et al. 2008). The
release of Survivin into the tumor microenvironment by malignant cells, while not
altering the CTL:Treg balance, is likely hampering CTL function by pushing the immune
response toward a type 2 and away from the type 1 response. In addition to its antiproliferative functions in T cells, these findings show that Survivin is capable of altering
the immune system towards a pro-tumor environment.

Materials & Methods
Analysis of CTL Cytotoxic Function
CD8+ CTLs were isolated from a single healthy donor using the MACS anti-PE
magnetic separation kit (Miltenyi Biotec, Auburn, CA) and anti-CD8 PE antibodies (BD
Biosciences, San Jose, CA). CTLs were cultured in 12-well plates in control, FLAG-HA

60

only or FLAG-HA-Survivin medium and stimulated with PMA (10ng/ml) and ionomycin
(0.1μg/ml). After 24 hours in culture the cells were washed and harvested. Pooled
PBMCs from various healthy donors were put into a 96-well plate with CTLs at 5:1,
2.5:1, and 1.25:1 (CTL:PBMC) ratios. The cytotoxic function of the CTLs was analyzed
using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Fitchburg, WI),
which measures the release of lactate dehydrogenase upon cell lysis.

Regulatory T Lymphocyte Analysis
CD3+ T lymphocytes were isolated and plated in 96-well in control, FLAG-HA
only or FLAG-HA-Survivin medium and stimulated for 48 hours with anti-CD3/antiCD28 T cell expansion beads (6.25μl/well; Invitrogen, Carlsbad, CA). Cells were stained
for CD3, CD4, CD8 (BioLegend, San Diego, CA), CD25 and CD127 (BD Biosciences,
San Jose, CA) and CD4+CD25+CD127low Treg populations analyzed by flow cytometry.

Regulatory T Lymphocyte Activity Assay
T regulatory cells were isolated from PBMCs using the EasySep Human
CD4+CD127low T Cell Enrichment Kit (Stem Cell Technologies, Vancouver, BC,
Canada) and cultured in 12-well plates at 1x106 cells/ml in control, FLAG-HA, or FLAGHA-Survivin medium. After 24 hours, cells were washed, harvested and added to
PBMCs at a 0:1, 0.25:1 or 0.5:1 (Treg:PBMC) concentration. Inhibition of cell activation
by Tregs was evaluated using the BD FastImmune Human Regulatory T Cell Function
Kit (BD Biosciences, San Jose, CA) and measuring the suppression of CD154 and CD69
induction by flow cytometry.
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Intracellular Cytokine Analysis
CD3+ T lymphocytes were isolated, plated in 96-well plates as described above
and stimulated with PMA (10ng/ml) and ionomycin (0.1μg/ml) in the presence of 3 μM
monensin to inhibit cytokine release. After 6 hours of activation, the cells were harvested
and stained for T lymphocyte surface markers. Cells were fixed and permeabilized and
intracellularly stained with biotinylated antibodies against IFN-γ, IL-4, IL-5, or IL-13
followed by streptavidin-APC (eBioscience, San Diego, CA). Stained cells were
evaluated using the MACSQuant flow cytometer.

Cytokine ELISA
Isolated CD8+ cells were stimulated with anti-CD3/anti-CD28 microbeads for 48
hours and PMA and ionomycin added for the final 6 hours. Cell supernatants were
isolated and analyzed using Ready-Set-Go! ELISAs (eBioscience) for concentrations of
IFN- γ, IL-2, IL-4, IL-5, IL-10, and IL-13.
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CHAPTER FIVE
ALTERATION OF HELPER T LYMPHOCYTES BY
SURVIVIN
Introduction
The tumor microenvironment is characterized by the infiltration of T cells (Liao Y
et al. 2007; Whiteside TL 2008). Investigation into the role of T cells in tumor
progression has demonstrated the importance of the inflammatory T cell response in
elimination of neoplastic cells (Hamai A et al. 2010). The importance of T cell subsets in
the anti-tumor response is of interest as imbalances in these cells and the cytokines they
produce have been shown to alter the ability of the immune system to eradicate the tumor
(Whiteside TL 2008). Of particular interest are the type 1 and type 2 T cells, which are
characterized by production of IFN-γ and IL-2 or IL-4 and IL-10, respectively (Zhu J and
Paul WE 2008).
Peripheral blood and intratumoral T cells from cancer patients frequently exhibit
altered T cell populations. Type 1 responses are typically decreased with a concomitant
increase in type 2 cell numbers and cytokine levels (Filella X et al. 2000; Ito N et al.
2001; Mainou-Fowler T et al. 2003; Ehi K et al. 2008). The potential for metastasis and
angiogenesis is increased by the presence of IL-4 and IL-6, respectively, and the type 2
polarization increases both of these cytokines (Naldini A et al. 2003; DeNardo DG et al.
2009). This shift is correlated to poor disease progression, as the anti-tumor response is
inhibited and a pro-tumor environment is created (Filella X et al. 2000; Murakami H et
al. 2004; Ehi K et al. 2008). Th17 cells, which release pro-inflammatory cytokines IL-17
and IL-21, have been implicated in the progression of malignancy in prostate and
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colorectal cancers(Liu J et al. 2011) (Sfanos KS et al. 2008). However, in breast cancer a
reduced number of Th17 cells is linked to poor prognosis (Yang L et al. 2012). The
exact role of these cells in tumor progression seems to be cancer-type specific. While
altered T cell populations in the tumor have been well documented from a clinical aspect,
what leads to these changes has not been fully elucidated. Here we propose that Survivin
could play a role in this helper T lymphocyte shift to a predominately type 2 phenotype.

Results & Discussion
Helper T Lymphocyte Subset Analysis
Intracellular Cytokine Analysis
After 6 hours of stimulation the cells were stained and evaluated for IFN-, IL-4,
IL-5, and IL-13 expression. A significant reduction in CD8+IFN-+ Tc1 cells was seen
after culture with Survivin, demonstrating a reduction in pro-inflammatory cells (Figure
4.4A,B). Additionally, CD8+ cells expressing the type 2 cytokines IL-5 and IL-13
increased substantially in FLAG-HA-Survivin cultures though the change in IL-4
expressing CD8+ cells was not significant (Figure 4.4B).
To evaluate the effects of tumor-released Survivin in T cell population skewing,
intracellular cytokine staining was used to quantify the number of Th1, Th2, and Th17
cells (Figure 5.1). Isolated T lymphocytes were cultured in control, FLAG-HA only or
FLAG-HA-Survivin medium for 48 hours and then stimulated in the presence of cytokine
release inhibitors. Figure 5.1A shows representative gating of intracellular cytokine
analysis for CD4+ T cells. As was observed in the cytotoxic T cell population, numbers
of Th1 (CD4+IFN-+) cells were significantly decreased in Survivin-containing cultures
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(Figure 5.1B). Additionally, Th2 cells expressing the cytokines IL-4, IL-5 and IL-13
increased substantially in FLAG-HA-Survivin cultures (Figure 5.1B). Evaluation of
Th17 cells by expression of IL-17 showed no difference in cell numbers in the presence
of Survivin (Figure 5.2). Due to the variable role of Th17 cells in cancer it is not
surprising that the ubiquitously expressed Survivin does not have a substantial affect on
this cell population.

Cytokine ELISA
To determine if this adjustment in cell numbers correlates to changes in cytokine
release, isolated CD4+ cells were plated in control, FLAG-HA only or FLAG-HASurvivin medium for 48 hours, and the culture supernatants evaluated by ELISA (Figure
5.3). Production of the Th1 cytokines IFN- and IL-2 was significantly reduced, which
correlates well with our observation that Th1 cell numbers were significantly reduced in
Survivin-containing cultures. Because IFN- is necessary for perpetuating the
differentiation of naïve T cells into Tc1 and Th1 cells, this reduction in IFN- could
enhance what we previously observed in the cytotoxic T cells, resulting in blunted
cytotoxic activity of CTLs. Additionally, the significant drop in IL-2 could play a part in
the decreased proliferation following activation of T cells, as IL-2 is necessary in
inducing cell division and clonal expansion of activated T cells.
Secretion of the Th2 cell cytokines showed variable changes in release after
culture with Survivin. Although the number of cells expressing IL-4, IL-5 and IL-13 all
increased based on intracellular cytokine flow cytometry, only the quantities of IL-4 and
IL-13 release was significantly increased when cultured with FLAG-HA-Survivin (Figure
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5.3). No significant change was seen in IL-5 or IL-10 levels (Figure 5.3). This shows
that Survivin does mediate a shift toward a Th2-dominant population, but does not
increase the levels of all Th2 cytokines.
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Figure 5.1. Flow Cytometric Analysis of Helper T Lymphocyte Subsets. A. Gating
scheme for CD4+ T cell subsets. B. Survivin significantly decreases CD4+IFN-γ+
cell numbers and increases CD4+Il-5+, CD4+IL-13+, and CD4+IL-4+ cell numbers.
*p<0.05, **p<0.01 and ***p<0.001.
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Figure 5.2. Analysis of IL-17 expression in T lymphocytes. A. Representative gating
scheme. B. Percent IL-17 expressing CD4+ T lymphocytes were not altered in the
presence of FLAG-HA-Survivin.
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Figure 5.3. ELISA Analysis of Helper T Cell Cytokines. Type 1 cytokines are decreased
and Type 2 cytokines increased by Survivin. Cytokine ELISA shows decreased
production of inflammatory cytokines IFN-γ and IL-2 by CD4+ T cells and increased IL4 and IL-13 production in the presence of Survivin. No change was observed in IL-5 or
IL-10 release. *p<0.05, **p<0.01 and ***p<0.001.
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Conclusion
Alteration of the immune response toward the type 2 phenotype has been
demonstrated in many types of cancer, including lymphoma, breast, prostate and lung
cancer. Despite this important role in clinical malignancy the mechanism behind this
shift has remained elusive. In these studies we showed that the polarization of the helper
T cell response leading to a hindered pro-inflammatory response could be mediated by
tumor-released Survivin. The overall shift from a type 1 to a type 2 response was shown
both by the decrease in IFN-γ+ T cells and the increase in IL-4+, IL-5+ and IL-13+ T cells
in response to Survivin. These findings demonstrate a role for Survivin in mediating the
shift from a type 1 to a type 2 T cell response in the tumor microenvironment.

Materials & Methods
Intracellular Cytokine Analysis
CD3+ T lymphocytes were isolated, plated in 96-well plates in control, FLAG-HA
only or FLAG-HA-Survivin medium and stimulated with PMA (10ng/ml) and ionomycin
(0.1μg/ml) in the presence of 3 μM monensin to inhibit cytokine release. After 6 hours of
activation, the cells were harvested and stained for T lymphocyte surface markers. Cells
were fixed and permeabilized and intracellularly stained with biotinylated antibodies
against IFN-γ, IL-4, IL-5, IL-13, or IL-17 followed by streptavidin-APC (eBioscience,
San Diego, CA). Stained cells were evaluated using the MACSQuant flow cytometer.

Cytokine ELISA
Isolated CD4+ cells were stimulated with anti-CD3/anti-CD28 microbeads for 48
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hours and PMA and ionomycin added for the final 6 hours in the presence or absence of
Survivin. Cell supernatants were isolated and analyzed using Ready-Set-Go! ELISAs
(eBioscience) for concentrations of IFN- γ, IL-2, IL-4, IL-5, IL-10, IL-13 and IL-17.
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CHAPTER SIX
CONCLUSIONS
Summary of Findings
Our studies isolated FLAG-HA tagged Survivin released from malignant cells and
characterized its effects on normal T lymphocytes. Evaluation of Survivin’s effects on T
cells demonstrated its ability to diminish their proliferation without altering their ability
to be activated by the proper stimuli. Additionally, Survivin diminishes cytotoxic T cell
function by altering the cytokine environment. The large reduction in inflammatory T
cells and cytokines, as well as the increase in type 2 T cells by Survivin coincides with
what has been seen in cancer patients and supports our hypothesis that extracellular
Survivin acts as an immune mediator. From our data we can conclude that: 1)
Extracellular Survivin can bind to and be taken up into normal T lymphocytes; 2) Uptake
of Survivin diminishes clonal expansion of T lymphocytes; and 3) Survivin shifts the T
cell population toward a type 2 phenotype, but does not alter the regulatory T or Th17
populations.

Tumor-Released Survivin Alters the T Lymphocyte Population
In chapter 2 we demonstrated that the tumor-released protein Survivin could be
isolated from conditioned medium, and upon addition to T cell cultures, is able to bind to
and be taken up by T cells. Like that described by Mera et al. (2008) using recombinant
protein, tumor-released Survivin is able to bind to the surface of T cells, and as
demonstrated in our studies, is also taken up into T cells. This data supports our
hypothesis that Survivin uptake could occur within the tumor microenvironment as a
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means of modulating T lymphocyte function. The inhibition of T lymphocyte division by
Survivin detailed in chapter 3 is in contrast to its effects on malignant cells (Khan S et al.
2009). While in malignant cells uptake of Survivin induced proliferation, T cell division
is hindered. Based on the evaluation of activation markers CD25 and CD69, Survivin is
not inhibiting T cell stimulation, but is possibly acting downstream of activation
signaling. Additionally, no changes in activation-induced endogenous Survivin in the
presence of FLAG-HA-Survivin were observed. As discussed in chapters 4 and 5, the
dramatic changes in IL-2 production in the presence of Survivin it is possible that the
mechanism of decreased proliferation is related to cytokine effects.
In addition to their decreased proliferative capacity, Survivin-exposed CD8+ T
cells exhibited decreased cytotoxic function compared to controls. Many previous
studies have demonstrated the inhibition of tumor-specific CTL function by T regulatory
(Treg) cells (Chattopadhyay S et al. 2006; James E et al. 2010). However in our studies,
Survivin did not significantly alter Treg numbers or function. Because of these
observations, we hypothesize that Survivin’s inhibition of cytotoxic function is
independent of Treg-mediated CTL suppression. Based on our data in chapters 4 and 5,
we believe changes to the cytokine profile and decreased IFN-γ production is likely
responsible for this suppression. The release of Survivin may be one mechanism by
which tumors evade T cell-mediated cytotoxicity.
Although Treg populations were not affected by extracellular Survivin, type 1 and
type 2 T cell populations were significantly altered. The decrease in IFN-γ and IL-2
production by T cells, combined with the significant drop in IFN-γ+ cells demonstrates an
inhibition of the anti-tumor response. The importance of IFN-γ to immune surveillance
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has been shown previously in spontaneous malignancy in IFN-γ deficient mice.
Additionally, it is frequently decreased in cancer patients (Filella X et al. 2000; Ellyard JI
et al. 2007; Ehi K et al. 2008; Hamai A et al. 2010). The overall shift from a type 1 to a
type 2 response was shown both by the decrease in IFN-γ+ T cells and the increase in IL4+, IL-5+ and IL-13+ T cells in response to tumor-released Survivin.
The importance of CD4+IL-4+cells in malignancy was recently demonstrated in a
mouse mammary carcinoma model, in which production of IL-4 by helper T cells was
able to polarize macrophages, resulting in increased lung metastasis (DeNardo DG et al.
2009). Similarly, increased plasma levels of IL-13 in patients with pancreatic, gastric and
esophageal cancers was positively correlated to increased numbers of myeloid derived
suppressor cells (Gabitass RF et al. 2011). Both these studies showed important
downstream effects of the shift to a type 2 response, but did not examine the preliminary
cause of the shift. Importantly, when combined with this study and our previous work
showing Survivin-associated invasiveness (Khan S et al. 2009), a more complete picture
emerges with Survivin inducing the type 2 response, which can then lead to increased
metastasis and complete polarization of the immune response.
Alteration of the immune response toward the type 2 phenotype has been
demonstrated in many types of cancer, including lymphoma, breast, prostate and lung
cancer, though the reason for this shift was undetermined (Filella X et al. 2000;
Nakayama H et al. 2000; Ito N et al. 2001; Mainou-Fowler T et al. 2003; Ehi K et al.
2008). Similar studies have been performed looking at Th17 cells in cancer patients
(Sfanos KS et al. 2008; Kryczek I et al. 2009; Yang ZZ et al. 2009; Maniati E et al.
2010). Unlike the Th1/Th2 shift, which is common across patients with a variety of
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cancer types, the role of Th17 cells appear to be cancer-type specific. In prostate and
ovarian cancers, increased numbers of Th17 cells in the tumor correlated with better
patient outcome, demonstrating an anti-tumor role (Sfanos KS et al. 2008; Kryczek I et
al. 2009). Conversely, in colorectal carcinoma, higher levels of serum IL-17 correlated
to poor patient prognosis (Liu J et al. 2011). In our studies, no change in IL-17expressing cells was observed after exposure to Survivin (Supplementary Figure 7),
unlike our observed type 1 and type 2 T cell shift.

Clinical Implications
In this study we show that the polarization of the T cell response leading to a protumor response could be mediated in part by tumor-released Survivin. The ability of
Survivin to decrease the proliferation and cytotoxicity of T cells and alter the T cell
response to malignant cells, as well as positively affect tumor growth and aggressiveness,
makes it an important therapeutic target for the treatment of cancer.
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